Recent events
Recent events tied to this brand in public sources.
Back to profile95 entries · Page 1 of 5
2026
AstraZeneca announces $2bn restructuring programme
AstraZeneca announced a three-year $2bn restructuring programme to reallocate resources across its business and therapy areas, with annual savings intended to be channelled back into the programme.
2026
AstraZeneca and Oracle announce AI clinical-trials collaboration
AstraZeneca said it is working with Oracle to use AI and real-world data to identify eligible patients for clinical trials and monitor safety signals. The first project will support hypertension research in Abu Dhabi in partnership with M42.
2026
AstraZeneca strikes $40 million AI drug discovery deal with insitro
AstraZeneca has struck a $40 million artificial intelligence drug discovery deal with insitro, as reported by Reuters.
2026
AstraZeneca and Daiichi Sankyo partner with Summit to test cancer drug combination
AstraZeneca and Daiichi Sankyo have partnered with Summit to test a cancer drug combination, as reported by Reuters.
2026
Summit Therapeutics announces $2 billion investment from AstraZeneca with clinical collaboration
Summit Therapeutics announced a $2 billion investment from AstraZeneca. Summit said it has established agreements with AstraZeneca for a strategic equity investment in Summit and a clinical collaboration focused on ivonescimab and sonesitatug vedotin (sone-ve), drugs aimed at treating cancer. Summit shares surged 18% in premarket trading.
2026
AstraZeneca invests billions in a cancer company
AstraZeneca is reported to be investing billions in a cancer company, according to a Medwatch report; the supplied evidence does not name the target company or provide further details.
2026
AstraZeneca sues International Fire Consultants for £32 million over Discovery Centre defects
AstraZeneca has launched a £32 million High Court claim against fire consultancy International Fire Consultants (IFC), alleging that IFC failed to comply with its duties and caused widespread defects in the construction of AstraZeneca's Discovery Centre in Cambridge. AstraZeneca says remediation work between 2021 and 2023 cost over £31.7 million. IFC has filed a defence calling the claim misconceived and incorrect, and AstraZeneca has issued a court reply rejecting that defence.
2022
AstraZeneca announces Ghana Living Lab partnership
AstraZeneca announced a partnership with the Circular Bioeconomy Alliance and local partners to establish the first Living Lab in Ghana. The community-led project aims to plant 4.5 million trees by the end of 2025, with over 3 million surviving trees.
2022
Bristol Myers Squibb sues AstraZeneca over cancer-treatment patents
Bristol Myers Squibb sued AstraZeneca in Delaware federal court, alleging that AstraZeneca's use of Imfinzi to treat lung and bladder cancer infringes patents related to Opdivo. Bristol Myers sought monetary damages.
2022
Alexion and Chugai settle Ultomiris patent disputes
Alexion, part of AstraZeneca's Rare Disease group, entered into a settlement agreement with Chugai resolving their patent disputes related to Ultomiris. The parties took steps to withdraw patent infringement proceedings filed in US and Japanese courts. Alexion will make a single payment of $775 million in the second quarter of 2022.
2022
AstraZeneca and Chugai settle Ultomiris patent litigation
AstraZeneca announced an agreement with Chugai Pharmaceutical resolving all patent disputes related to Ultomiris. Alexion, AstraZeneca's Rare Disease group, will make a single payment of $775 million in the second quarter of 2022.
2022
Bristol-Myers Squibb sued AstraZeneca over alleged patent infringement
Bristol-Myers Squibb and E.R. Squibb & Sons filed suit against AstraZeneca entities in the District of Delaware, alleging that marketing durvalumab infringed their patents. The plaintiffs sought damages and an injunction; the source reports allegations, not a court determination.
2022
Ping An Health and AstraZeneca China sign strategic partnership
Ping An Health and AstraZeneca China signed a strategic cooperation agreement to collaborate on pharmaceutical retail ecosystem innovation and chronic disease management, and to explore online healthcare service models.
2022
Covis completes acquisition of respiratory medicines from AstraZeneca
Covis Pharma completed its acquisition from AstraZeneca of Eklira and Duaklir, including the medicines' listed market names in some countries. AstraZeneca received a $270 million payment and will also receive payments related to certain ongoing development costs.
2021
FDA approves Tezspire for severe asthma
The U.S. Food and Drug Administration approved Tezspire, developed by Amgen and AstraZeneca, as add-on maintenance treatment for adult and pediatric patients aged 12 years and older with severe asthma.
2021
AstraZeneca partners on UK tree-planting programme
AstraZeneca UK partnered with Forestry England and Borders Forest Trust on a multi-year tree-planting programme, aiming to plant more than one million trees across the UK by 2025 through a £1.9 million investment.
2021
AstraZeneca opens Cambridge R&D centre
AstraZeneca opened its new £1bn research and development centre in Cambridge on Tuesday. The facility houses 16 labs and 2,200 scientists.
2021
NCCN and AstraZeneca collaborate to fund lung cancer research projects
NCCN's Oncology Research Program announced funding for early-stage non-small cell lung cancer projects with support from AstraZeneca; the announced grants total approximately $1.3 million collectively.
2021
Daily Express corrects false claim about AstraZeneca vaccine formula
The Daily Express corrected an article that falsely claimed Russia copied the AstraZeneca vaccine formula to make its own vaccine. The outlet apologized and published the Russian Direct Investment Fund’s response. The claim concerned AstraZeneca, but the source does not establish that the formula was stolen.
2021
AstraZeneca withdraws Forxiga indication for type 1 diabetes in Europe
AstraZeneca withdrew dapagliflozin (Forxiga) from the market in EU countries for the type 1 diabetes indication. The report says the company stated that the decision was not motivated by safety concerns; the type 2 diabetes and other listed indications were unaffected.